Transarterial embolisation with bleomycin and N-butyl-2-cyanoacrylate –Lipiodol mixture for symptomatic polycystic liver disease: preliminary experience

Yan, Jieyu; Zhang, J.L.; Yuan, Kai; Fu, Jinxin; Wang, Y.; Yuan, Bing; Wang, M.Q.

doi:10.1016/j.crad.2019.08.009

Cited by 10 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some series have demonstrated that transarterial embolisation of the hepatic arteries may reduce cyst volume in PLD but the experience with this intervention is limited. 172…”

Section: Interventional (Radiological) Treatmentmentioning

confidence: 99%

EASL Clinical Practice Guidelines on the management of cystic liver diseases

Drenth¹,

Barten²,

Hartog³

et al. 2022

Journal of Hepatology

View full text Add to dashboard Cite

“…Some series have demonstrated that transarterial embolisation of the hepatic arteries may reduce cyst volume in PLD but the experience with this intervention is limited. 172…”

Section: Interventional (Radiological) Treatmentmentioning

confidence: 99%

EASL Clinical Practice Guidelines on the management of cystic liver diseases

Drenth¹,

Barten²,

Hartog³

et al. 2022

Journal of Hepatology

View full text Add to dashboard Cite

“…Recurrence of symptoms is frequent in the context of PLD 66,169,171 (see question 4). Some series have demonstrated that transarterial embolisation of the hepatic arteries may reduce cyst volume in PLD but the experience with this intervention is limited 172 .…”

Section: Interventional (Radiological) Treatmentmentioning

confidence: 99%

Clinical guidance for polycystic liver disease

Barten

2023

View full text Add to dashboard Cite

Polycystic liver disease is characterized by fluid-filled cysts in the liver. Pressure from these cysts on surrounding structures causes symptoms. The severity of this disease can be determined using the total liver volume or by recording the symptom burden. This thesis demonstrates the speed and precision of various (semi-)automatic methods to calculate total liver volume. It also improves the clinical application of a polycystic liver disease specific symptom questionnaire (the PLD-Q) and demonstrates the prognostic value of total liver volume. Finally, this thesis provides clinical guidelines regarding abdominal wall hernias, diagnosis and treatment of cystic liver diseases, and future therapeutic targets for polycystic liver disease.

show abstract

“…There was also a reduction in total liver volume, from 9,776 ± 2,219 cm 3 in the pre-treatment to 8,303 ± 2,009 cm 3 6–12 months after the procedure. 242 Despite the expressive results, a retrospective study involving 18 patients undergoing TAE in PLD treatment showed a significant rate of treatment failure. Of the 23 procedures performed during the study, only seven showed satisfactory results; that is, the treatment failure rate was 69.6%.…”

Section: Treatmentmentioning

confidence: 99%

Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment

Norcia¹,

Watanabe²,

Filho³

et al. 2022

HMER

View full text Add to dashboard Cite

Polycystic liver disease (PLD) is a clinical condition characterized by the presence of more than 10 cysts in the liver. It is a rare disease Of genetic etiology that presents as an isolated disease or assoc\iated with polycystic kidney disease. Ductal plate malformation, ciliary dysfunction, and changes in cell signaling are the main factors involved in its pathogenesis. Most patients with PLD are asymptomatic, but in 2-5% of cases the disease has disabling symptoms and a significant reduction in quality of life. The diagnosis is based on family history of hepatic and/or renal polycystic disease, clinical manifestations, patient age, and polycystic liver phenotype shown on imaging examinations. PLD treatment has evolved considerably in the last decades. Somatostatin analogues hold promise in controlling disease progression, but liver transplantation remains a unique curative treatment modality.

show abstract

Transarterial embolisation with bleomycin and N-butyl-2-cyanoacrylate –Lipiodol mixture for symptomatic polycystic liver disease: preliminary experience

Cited by 10 publications

References 19 publications

EASL Clinical Practice Guidelines on the management of cystic liver diseases

EASL Clinical Practice Guidelines on the management of cystic liver diseases

Clinical guidance for polycystic liver disease

Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment

Contact Info

Product

Resources

About